Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Dr. Seymour Discusses the Results of the PRIMA Study

April 28th 2014

John F. Seymour, MBBS, FRACP, PhD, from the Department of Hematology at the Peter MacCallum Cancer Centre in East Melbourne, Australia, discusses the results of the PRIMA study, which evaluated the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy in patients with advanced follicular lymphoma.

Dr. Melnick on Targeting EZH2 in DLBCL

April 10th 2014

Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B-cell lymphoma.

Dr. Melnick on Epigenetic Diversity in DLBCL

March 3rd 2014

Ari Melnick, MD, professor of medicine, Weill Cornell Medical College, discusses the association between epigenetic diversity and clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL).

Changing Therapeutic Landscape in ALL, CLL, and NHL

January 22nd 2014

Combination Therapy in Large Cell Lymphomas

January 22nd 2014

Brentuximab Vedotin in Diffuse Large B-cell Lymphoma

January 22nd 2014

PI3K Inhibition in Hematologic Malignancies

January 22nd 2014

Bcl-2 Inhibition With ABT-199 in CLL, Lymphomas

January 22nd 2014

Combining and Sequencing New Agents in CLL

January 22nd 2014

Efficacy and Future Role of Ibrutinib in CLL and MCL

January 22nd 2014

Surrogate Endpoints for New Drug Discovery in ALL

January 22nd 2014

Emerging Strategies in the Treatment of ALL

January 22nd 2014

Novel Therapies for Patients Ph-Negative ALL

January 22nd 2014

Introduction: Treating ALL in Adult Patients

January 22nd 2014

Anti-PD-1 Antibody Pidilizumab Shows Promise in Diffuse Large B-Cell Lymphoma

January 17th 2014

The anti-PD-1 monoclonal antibody pidilizumab showed promising clinical activity and was safely administered to patients with diffuse large B-cell lymphoma after autologous hematopoietic stem-cell transplantation.

Brentuximab Vedotin Shows Activity in B-Cell Lymphomas

December 12th 2013

Brentuximab vedotin has demonstrated antitumor activity in the setting of relapsed or refractory DLBCL across a broad range of CD30 expression, including low or undetectable CD30 expression.

Dr. Seymour on the Efficacy of ABT-199 in High-Risk CLL

December 8th 2013

John F. Seymour, MBBS, FRACP, PhD, discusses the efficacy of single-agent ABT-199 (GDC-0199), a novel Bcl-2 inhibitor, in high-risk relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. van den Brink on Adding Ibrutinib to R-CHOP in NHL

December 4th 2013

Marcel R.M. van den Brink, MD, PhD, Head, discusses a trial being presented at the 2013 ASH Annual Meeting, analyzing the addition of ibrutinib to R-CHOP in patients with non-Hodgkin's lymphoma (NHL).

Novel B-Cell Receptor Signaling Inhibitors Show Promise

October 23rd 2013

Drugs targeting B-cell receptor signaling pathways are improving outcomes for patients with B-cell lymphomas; these novel agents include idelalisib and ibrutinib, and are considered a breakthrough for CLL and other B-cell lymphomas.

Ibrutinib Combo Achieves 100% Response Rate in Patients With NHL

August 15th 2013

Adding ibrutinib to standard R-CHOP chemotherapy for non-Hodgkin lymphoma resulted in an objective response rate of 100% in the first-line setting.